Initial $4.8bn Outlay To Back India's COVID-19 Vaccination Run
Part Of $30bn Allocation For Health Amid Pandemic
Executive Summary
Significant allocations for public health programs and vaccination are prominent features of India's budget for fiscal 2021-22, though execution of these plans will be critical. Pharma is also keenly tracking a proposed allocation to bolster the overall research ecosystem and opening up of the insurance sector to foreign ownership.
You may also be interested in...
Is India’s Budget Bad News For COVID-19 Boosters, New Vaccines?
India’s 2022-23 budget cuts the outlay for COVID-19 vaccines to a seventh the previous amount. Is that worrying or does it leave the door open for private sales of vaccines? With over 75% of the country's adult population now fully vaccinated, what does it mean for booster shots and yet to be approved SARS-CoV-2 vaccines?
India’s COVID-19 Nightmare And How Pharma Is Holding Up
A COVID-19 second wave is wreaking havoc in India but pharma appears to be holding things together for now, stretching resources amid a dip in personnel attendance and supply chain strains. Limited vaccine supplies, a spurt in API prices and an inevitable third wave could mean further turbulence ahead.
India’s COVID-19 Nightmare And How Pharma Is Holding Up
A COVID-19 second wave is wreaking havoc in India but pharma appears to be holding things together for now, stretching resources amid a dip in personnel attendance and supply chain strains. Limited vaccine supplies, a spurt in API prices and an inevitable third wave could mean further turbulence ahead.